株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

尋常性座瘡 : パイプライン製品の分析

Acne Vulgaris - Pipeline Review, H1 2017

発行 Global Markets Direct 商品コード 232807
出版日 ページ情報 英文 177 Pages
即納可能
価格
本日の銀行送金レート: 1USD=112.28円で換算しております。
Back to Top
尋常性座瘡 : パイプライン製品の分析 Acne Vulgaris - Pipeline Review, H1 2017
出版日: 2017年05月09日 ページ情報: 英文 177 Pages
概要

尋常性座瘡とは、顔および上躯幹の毛包脂腺小胞の異常であり、吹き出ものが炎症を起こし、膿疱、結節、嚢胞などになると、痛みを持つ場合もあります。青年期、ヘアジェル、油性の化粧品、ヘルメットのストラップの摩擦などスポーツ用品、皮膚の閉塞などが素因となり、抗生物質で治療します。

当レポートでは、世界における尋常性座瘡治療薬のパイプラインについて取り上げ、現在の開発パイプラインの状況や最新動向、薬剤プロファイル、主要企業および開発中の製品レビューなどをお届けいたします。

目次

イントロダクション

  • 分析範囲

尋常性座瘡の概要

治療薬の開発

  • 尋常性座瘡向けパイプライン製品:概要
  • 尋常性座瘡:開発中の治療薬:企業別
  • 尋常性座瘡:開発中の治療薬:大学・研究機関別
  • 尋常性座瘡:開発中の製品:企業別
  • 尋常性座瘡:開発中の製品:大学・研究機関別

尋常性座瘡:治療薬の評価

  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

尋常性座瘡:治療薬開発に従事している企業

  • 3SBio Inc
  • Allergan Plc
  • Almirall SA
  • Biomar Microbial Technologies
  • BioPharmX Inc
  • Braintree Laboratories Inc
  • Brickell Biotech Inc
  • Cassiopea SpA
  • Cell Medica Ltd
  • Cellceutix Corp
  • Celtaxsys Inc
  • Common Pharma Inc
  • Cutanea Life Sciences Inc
  • Dermira Inc
  • ELORAC Inc
  • Ensol Biosciences Inc
  • Foamix Pharmaceuticals Ltd
  • Galderma SA
  • GlaxoSmithKline Plc
  • Helix BioMedix Inc
  • Hovione FarmaCiencia SA
  • Lee's Pharmaceutical Holdings Ltd
  • LEO Pharma A/S
  • Novabiotics Ltd
  • Novan Inc
  • Novartis AG
  • Paratek Pharmaceuticals Inc
  • Pfizer Inc
  • Phosphagenics Ltd
  • Photocure ASA
  • Promius Pharma LLC
  • Provectus Biopharmaceuticals Inc
  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
  • Sol-Gel Technologies Ltd
  • Sun Pharma Advanced Research Company Ltd
  • Valeant Pharmaceuticals International Inc
  • Vectura Group Plc
  • Vyome Biosciences Pvt Ltd
  • XBiotech Inc

薬剤プロファイル

休止中のプロジェクト

開発中止の製品

製品開発マイルストーン

  • 注目のニュース・プレスリリース

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC9230IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Acne Vulgaris - Pipeline Review, H1 2017, provides an overview of the Acne Vulgaris (Dermatology) pipeline landscape.

Acne vulgaris is a chronic skin disease involving blockage and inflammation of pilosebaceous follicles. Symptoms include crusting of skin bumps, cysts, papules (small red bumps), scarring of the skin and redness around the skin eruptions. The predisposing factors include adolescence, hair gels or oil-based cosmetics, sports equipment such as helmet straps rubbing and occluding skin. Treatment includes antibiotics.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Acne Vulgaris - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Acne Vulgaris (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Acne Vulgaris (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Acne Vulgaris and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 10, 21, 6, 1, 16, 4 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 2 molecules, respectively.

Acne Vulgaris (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Acne Vulgaris (Dermatology).
  • The pipeline guide reviews pipeline therapeutics for Acne Vulgaris (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Acne Vulgaris (Dermatology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Acne Vulgaris (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Acne Vulgaris (Dermatology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Acne Vulgaris (Dermatology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Acne Vulgaris (Dermatology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Acne Vulgaris - Overview
    • Acne Vulgaris - Therapeutics Development
  • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Acne Vulgaris - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Acne Vulgaris - Companies Involved in Therapeutics Development
    • 3SBio Inc
    • Allergan Plc
    • Almirall SA
    • Biomar Microbial Technologies
    • BioPharmX Inc
    • Braintree Laboratories Inc
    • Brickell Biotech Inc
    • Cassiopea SpA
    • Cell Medica Ltd
    • Cellceutix Corp
    • Celtaxsys Inc
    • Common Pharma Inc
    • Cutanea Life Sciences Inc
    • Dermira Inc
    • ELORAC Inc
    • Ensol Biosciences Inc
    • Foamix Pharmaceuticals Ltd
    • Galderma SA
    • GlaxoSmithKline Plc
    • Helix BioMedix Inc
    • Hovione FarmaCiencia SA
    • Lee's Pharmaceutical Holdings Ltd
    • LEO Pharma A/S
    • Novabiotics Ltd
    • Novan Inc
    • Novartis AG
    • Paratek Pharmaceuticals Inc
    • Pfizer Inc
    • Phosphagenics Ltd
    • Photocure ASA
    • Promius Pharma LLC
    • Provectus Biopharmaceuticals Inc
    • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
    • Sol-Gel Technologies Ltd
    • Sun Pharma Advanced Research Company Ltd
    • Valeant Pharmaceuticals International Inc
    • Vectura Group Plc
    • Vyome Biosciences Pvt Ltd
    • XBiotech Inc
  • Acne Vulgaris - Drug Profiles
    • (adapalene + clindamycin hydrochloride) - Drug Profile
    • (benzoyl peroxide + tretinoin) - Drug Profile
    • (clindamycin phosphate + tretinoin) - Drug Profile
    • acebilustat - Drug Profile
    • Aczone Combo - Drug Profile
    • aminolevulinic acid hydrochloride - Drug Profile
    • AQ-401 - Drug Profile
    • B-244 - Drug Profile
    • BBI-3000 - Drug Profile
    • benzoyl peroxide - Drug Profile
    • BLI-1100 - Drug Profile
    • brilacidin tetrahydrochloride - Drug Profile
    • carbamide peroxide - Drug Profile
    • CB-0301 - Drug Profile
    • CB-0601 - Drug Profile
    • CJM-112 - Drug Profile
    • CLS-007 - Drug Profile
    • dapsone - Drug Profile
    • DFD-10 - Drug Profile
    • DLX-2323 - Drug Profile
    • DLX-2681 - Drug Profile
    • DMT-210 - Drug Profile
    • DMT-310 - Drug Profile
    • DX-0385 - Drug Profile
    • finasteride - Drug Profile
    • FMX-101 - Drug Profile
    • GSK-1940029 - Drug Profile
    • HB-1345 - Drug Profile
    • Hesed-4000 - Drug Profile
    • IB-07A037 - Drug Profile
    • IDP-120 - Drug Profile
    • IDP-121 - Drug Profile
    • IDP-123 - Drug Profile
    • IDP-126 - Drug Profile
    • IDP-129 - Drug Profile
    • IDP-130 - Drug Profile
    • ingenol disoxate - Drug Profile
    • ivermectin - Drug Profile
    • K-1032 - Drug Profile
    • LTA-001 - Drug Profile
    • methyl aminolevulinate hydrochloride - Drug Profile
    • minocycline - Drug Profile
    • minocycline - Drug Profile
    • minocycline hydrochloride - Drug Profile
    • MTC-896 - Drug Profile
    • olumacostat glasaretil - Drug Profile
    • omiganan pentahydrochloride - Drug Profile
    • Peptide to Disrupt Bacterial Cell Membrane and Cell Wall for Acne And Skin Cancer - Drug Profile
    • PF-06423264 - Drug Profile
    • PH-10 - Drug Profile
    • RA-18C3 - Drug Profile
    • sarecycline hydrochloride - Drug Profile
    • SB-204 - Drug Profile
    • SKP-026 - Drug Profile
    • Small Molecule for Acne and Skin Inflammation - Drug Profile
    • Small Molecule to Agonise NR1C3 for Acne Vulgaris - Drug Profile
    • Small Molecules for Acne Vulgaris - Drug Profile
    • Synthetic Peptide for Acne Vulgaris - Drug Profile
    • Synthetic Peptide to Inhibit SREBP1 for Acne, Amyotrophic Lateral Sclerosis and Stroke - Drug Profile
    • tazarotene - Drug Profile
    • tretinoin - Drug Profile
    • tretinoin - Drug Profile
    • trifarotene - Drug Profile
    • Vaccine for Acne Vulgaris - Drug Profile
    • VB-1953 - Drug Profile
  • Acne Vulgaris - Dormant Projects
  • Acne Vulgaris - Discontinued Products
  • Acne Vulgaris - Product Development Milestones
    • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Acne Vulgaris, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..2), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..3), H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Acne Vulgaris - Pipeline by 3SBio Inc, H1 2017
  • Acne Vulgaris - Pipeline by Allergan Plc, H1 2017
  • Acne Vulgaris - Pipeline by Almirall SA, H1 2017
  • Acne Vulgaris - Pipeline by Biomar Microbial Technologies, H1 2017
  • Acne Vulgaris - Pipeline by BioPharmX Inc, H1 2017
  • Acne Vulgaris - Pipeline by Braintree Laboratories Inc, H1 2017
  • Acne Vulgaris - Pipeline by Brickell Biotech Inc, H1 2017
  • Acne Vulgaris - Pipeline by Cassiopea SpA, H1 2017
  • Acne Vulgaris - Pipeline by Cell Medica Ltd, H1 2017
  • Acne Vulgaris - Pipeline by Cellceutix Corp, H1 2017
  • Acne Vulgaris - Pipeline by Celtaxsys Inc, H1 2017
  • Acne Vulgaris - Pipeline by Common Pharma Inc, H1 2017
  • Acne Vulgaris - Pipeline by Cutanea Life Sciences Inc, H1 2017
  • Acne Vulgaris - Pipeline by Dermira Inc, H1 2017
  • Acne Vulgaris - Pipeline by ELORAC Inc, H1 2017
  • Acne Vulgaris - Pipeline by Ensol Biosciences Inc, H1 2017
  • Acne Vulgaris - Pipeline by Foamix Pharmaceuticals Ltd, H1 2017
  • Acne Vulgaris - Pipeline by Galderma SA, H1 2017
  • Acne Vulgaris - Pipeline by GlaxoSmithKline Plc, H1 2017
  • Acne Vulgaris - Pipeline by Helix BioMedix Inc, H1 2017
  • Acne Vulgaris - Pipeline by Hovione FarmaCiencia SA, H1 2017
  • Acne Vulgaris - Pipeline by Lee's Pharmaceutical Holdings Ltd, H1 2017
  • Acne Vulgaris - Pipeline by LEO Pharma A/S, H1 2017
  • Acne Vulgaris - Pipeline by Novabiotics Ltd, H1 2017
  • Acne Vulgaris - Pipeline by Novan Inc, H1 2017
  • Acne Vulgaris - Pipeline by Novartis AG, H1 2017
  • Acne Vulgaris - Pipeline by Paratek Pharmaceuticals Inc, H1 2017
  • Acne Vulgaris - Pipeline by Pfizer Inc, H1 2017
  • Acne Vulgaris - Pipeline by Phosphagenics Ltd, H1 2017
  • Acne Vulgaris - Pipeline by Photocure ASA, H1 2017
  • Acne Vulgaris - Pipeline by Promius Pharma LLC, H1 2017
  • Acne Vulgaris - Pipeline by Provectus Biopharmaceuticals Inc, H1 2017
  • Acne Vulgaris - Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd, H1 2017
  • Acne Vulgaris - Pipeline by Sol-Gel Technologies Ltd, H1 2017
  • Acne Vulgaris - Pipeline by Sun Pharma Advanced Research Company Ltd, H1 2017
  • Acne Vulgaris - Pipeline by Valeant Pharmaceuticals International Inc, H1 2017
  • Acne Vulgaris - Pipeline by Vectura Group Plc, H1 2017
  • Acne Vulgaris - Pipeline by Vyome Biosciences Pvt Ltd, H1 2017
  • Acne Vulgaris - Pipeline by XBiotech Inc, H1 2017
  • Acne Vulgaris - Dormant Projects, H1 2017
  • Acne Vulgaris - Dormant Projects, H1 2017 (Contd..1), H1 2017
  • Acne Vulgaris - Dormant Projects, H1 2017 (Contd..2), H1 2017
  • Acne Vulgaris - Dormant Projects, H1 2017 (Contd..3), H1 2017
  • Acne Vulgaris - Dormant Projects, H1 2017 (Contd..4), H1 2017
  • Acne Vulgaris - Discontinued Products, H1 2017

List of Figures

  • Number of Products under Development for Acne Vulgaris, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Top 10 Targets, H1 2017
  • Number of Products by Stage and Top 10 Targets, H1 2017
  • Number of Products by Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top